The company will play a key role on the opening day, which includes an entire session dedicated to SLEEP HEALTH, highlighting the growing importance of sleep disorders in pulmonology and overall health.

Ugo Faraguna, President and Founder of Sleepacta and Professor of Physiology at the University of Pisa, will speak on Friday, December 5 at 10:30 with a presentation titled:

“Beyond Screening: Diagnostics and Innovation with Artificial Intelligence”

Prof. Faraguna’s talk will focus on how new technologies are revolutionizing sleep assessment, moving from invasive and costly methods to simple, objective, and certified solutions based on wearable devices and advanced algorithms.

Sleepacta, known for developing the certified medical algorithm Dormi, uses neural networks to analyze data collected from simple wearable devices (actigraphs). This approach enables accurate and non-invasive monitoring of sleep quantity and quality, which is essential not only for insomnia but also for screening respiratory disorders such as sleep apnea (with the specialized Dormi Apnea algorithm).

“Sleep is a crucial physiological parameter, yet its diagnosis has historically been complex and often underestimated. Today, Artificial Intelligence allows us to make a significant leap forward: combining scientific validity with unprecedented accessibility,” said Prof. Ugo Faraguna. “At PNEUMOROMA 2025, we will present how our AI-based solutions are helping clinicians—particularly pulmonologists—obtain objective and reliable data in an area of great interest such as respiratory sleep disorders.”

Sleepacta’s participation in the PNEUMOROMA 2025 congress confirms the company’s commitment to fostering innovation in digital diagnostics and supporting the medical community in managing sleep-related pathologies.